MedPath

Investigation of the effectiveness of resistant maltodextrin intake for 24 weeks on glycometabolism

Not Applicable
Conditions
Male and female who are aged 20 years and older and who have high HbA1c levels
Registration Number
JPRN-UMIN000023970
Lead Sponsor
CPCC Company Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

(1) Subjects who are diagnosed as diabetes and receiving treatment. (2) Subjects who constantly take oral medicines, functional foods and/or supplements that have a possibility to affect the test results. (3) Females who are pregnant or lactating, and females who have possibility of pregnancy. (4) Subjects who donated blood and/or blood components more than 200 mL within 4 weeks prior to the test. (5) Males who donated blood and/or blood components more than 400 ml within 12 weeks prior to the test. (6) Females who donated blood and/or blood components more than 400 ml within 16 weeks prior to the test. (7) Males who were collected blood and blood components more than 1200 ml within 12 months prior to the test when planned blood sampling amount of this test is added. (8) Females who were collected blood and blood components more than 800 ml within 12 months prior to the test when planned blood sampling amount of this test is added. (9) Subjects who are participating in other clinical tests, and/or subjects who participated in other clinical tests within 4 weeks prior to the test. (10) Subjects who consume excessive amount of alcohol or smoke heavily (more than 21 cigarettes a day). (11) Subjects who have extremely irregular dining habits, and/or subjects who work midnight or irregular shifts. (12) Subjects who falls under any of the following criteria. (a) Subjects who have heart disease, liver disease, or kidney disease (including the complication of other diseases). (b) Subjects who have medical history of cardiovascular diseases. (c) Subjects who are allergic to the test foods. (13) Subjects who are judged as unsuitable for this study by principal investigator or sub-investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
(1)Efficacy: HbA1c (2)Safety: The incidence of side effects
Secondary Outcome Measures
NameTimeMethod
(1)Efficacy: OGTT, GA, 1.5-AG, GLP-1, intestinal flora (2)Safety: The incidence of adverse events
© Copyright 2025. All Rights Reserved by MedPath